0.4600USDMkt Cap: 18.76M USDP/E: —Last update: 2026-05-21
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the U…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap18.76M USD
Enterprise Value10.38M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-8.48M USD
Revenue/Share—
Last Price0.4600 USD
Fiscal Year EndJun 2025
MR QuarterDec 2025
Employees2
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.73
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.47
EPS (TTM)-0.18
EPS (Forward)-0.65
52W Range
—
52W High0.4600 USD
52W Low0.4600 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-72.78%
ROA-69.86%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.35M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-20.12%
Net Debt-9.04M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio6.24
Quick Ratio6.12
Book Value/Sh0.1930 USD
Cash/Share0.2220 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.40.78M
Float24.13M
Insiders40.84%
Institutions0.00%
Short Interest
Short Ratio1.5d
Short % Float2.20%
Short % Out.0.36%
Shares Short146.37K
Short (prev mo.)58.05K
Technical
SMA 500.6202 (-25.8%)
SMA 2001.541 (-70.1%)
Beta-1.94
S&P 52W Chg28.31%
Avg Vol (30d)650
Avg Vol (10d)2.51K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—